Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute’s Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.

Guest:

Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Guest Host:

Dr. William S. Smith is Pioneer’s Visiting Fellow in the Life Sciences. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor’s office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer’s corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.

Get new episodes of Hubwonk in your inbox!

Recent episodes:

Hubwonk Ep. 5: COVID Calling: How answering the tracing phone call will move us forward

/
In this episode, Host Joe Selvaggi and Co-Host Barbara Anthony speak with the heads of Partners in Health Drs. Sheila Davis & John Welch on how they are bringing their expertise battling Ebola in West Africa to defeating the COVID-19 epidemic in Massachusetts. They explore precisely how and why tracing is an essential element in battling the epidemic.

Conquering COVID-19: When and From Where Will Vaccines and Therapies Emerge?

/
This week on Hubwonk, Host Joe Selvaggi is joined by Pioneer’s Bill Smith, Visiting Fellow in Life Sciences, and Dr. Peter Kolchinsky, Harvard-trained virologist, biotech investor and author of the new book, The Great American Drug Deal, to learn how the SARS-CoV2 works, what a vaccine may look like, and how we might produce it to scale.

A Tipping Point for Telehealth – Bringing Healthcare into Your Home

/
This week on "Hubwonk," Joe Selvaggi and Josh Archambault talk with Dr. Roy Schoenberg, Chief Executive of Amwell, a global telehealth technology company headquartered in Boston, about the promise of telemedicine and how the COVID-19 pandemic has catalyzed broader adoption.

Coronavirus & Contracts – Protecting Massachusetts Attorneys & Clients from Risk

/
In this episode of "Hubwonk," host Joe Selvaggi and Pioneer’s Chief Financial Officer & Director of Government Transparency, Mary Connaughton, speak with attorney and entrepreneur Kosta Ligris about how Massachusetts’ requirement for live attestation for many vital contracts is putting attorneys and clients at risk of exposure to coronavirus.

Buoy Health – Intelligent Front Door to Optimized Healthcare

/
In this first episode of Pioneer's new podcast, Hubwonk, host Joe Selvaggi and Pioneer Senior Fellow in Healthcare Josh Archambault talk with Dr. Andrew Le, cofounder and Chief Executive Officer of Buoy Health.

Pioneer Institute Launches Its New Policy Podcast, “HubWonk”

Pioneer Institute is pleased to announce the launch today of a new, weekly podcast called “HubWonk,” covering timely topics, with insights and in-depth interviews on the issues that affect our quality of life, ability to prosper, and liberties.